Lisa Ley

1.2k total citations
30 papers, 655 citations indexed

About

Lisa Ley is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Lisa Ley has authored 30 papers receiving a total of 655 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 8 papers in Surgery and 6 papers in Molecular Biology. Recurrent topics in Lisa Ley's work include Pancreatic and Hepatic Oncology Research (7 papers), Virus-based gene therapy research (4 papers) and Neuroendocrine Tumor Research Advances (4 papers). Lisa Ley is often cited by papers focused on Pancreatic and Hepatic Oncology Research (7 papers), Virus-based gene therapy research (4 papers) and Neuroendocrine Tumor Research Advances (4 papers). Lisa Ley collaborates with scholars based in United States, Netherlands and Italy. Lisa Ley's co-authors include J Koudstaal, G. Harms, Harry van Goor, Mj Hardonk, Elisabeth G.E. de Vries, Michael J. Pishvaian, Lou A. Smets, Geke A.P. Hospers, Nanno H. Mulder and Donald R. A. Uges and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Experimental Cell Research.

In The Last Decade

Lisa Ley

28 papers receiving 625 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lisa Ley United States	14	326	273	108	89	71	30	655
S. Streit Germany	7	364 1.1×	481 1.8×	130 1.2×	138 1.6×	63 0.9×	8	823
Julia Kirshner United States	15	379 1.2×	368 1.3×	97 0.9×	75 0.8×	58 0.8×	30	848
P.M. Martin France	17	357 1.1×	367 1.3×	170 1.6×	118 1.3×	42 0.6×	59	895
Abbey L. Wentzel United States	9	344 1.1×	335 1.2×	95 0.9×	84 0.9×	31 0.4×	10	568
Kenneth E. Hook United States	9	338 1.0×	415 1.5×	61 0.6×	109 1.2×	73 1.0×	15	785
Junhye Kwon South Korea	18	274 0.8×	594 2.2×	205 1.9×	93 1.0×	99 1.4×	31	854
Víctor J. Sánchez‐Arévalo Lobo Spain	14	311 1.0×	693 2.5×	152 1.4×	44 0.5×	61 0.9×	23	887
Thomas Waerner Germany	10	306 0.9×	636 2.3×	150 1.4×	59 0.7×	74 1.0×	13	866
Edwardine Nodzenski United States	14	225 0.7×	613 2.2×	185 1.7×	73 0.8×	80 1.1×	22	916
Michele Dziubinski United States	14	547 1.7×	545 2.0×	172 1.6×	57 0.6×	51 0.7×	17	890

Countries citing papers authored by Lisa Ley

Since Specialization

Citations

This map shows the geographic impact of Lisa Ley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Ley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Ley more than expected).

Fields of papers citing papers by Lisa Ley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Ley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Ley. The network helps show where Lisa Ley may publish in the future.

Co-authorship network of co-authors of Lisa Ley

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Ley. A scholar is included among the top collaborators of Lisa Ley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Ley. Lisa Ley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Simon, Nicholas I., Daniel M. Girardi, Lisa Ley, et al.. (2025). A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (laser)—design and rationale. Future Oncology. 21(10). 1171–1177.

Simon, Nicholas I., Daniel M. Girardi, Lisa Ley, et al.. (2025). E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale. Future Oncology. 21(13). 1625–1630. 1 indexed citations

Simon, Nicholas I., Daniel M. Girardi, Lisa Ley, et al.. (2024). A phase II multicenter study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors (E-VIRTUE).. Journal of Clinical Oncology. 42(16_suppl). TPS4628–TPS4628.

Simon, Nicholas I., Scot A. Niglio, Lisa Ley, et al.. (2024). A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (LASER).. Journal of Clinical Oncology. 42(16_suppl). TPS4629–TPS4629. 1 indexed citations

Simon, Nicholas I., Lisa M. Cordes, Elizabeth Smith, et al.. (2024). SMART: A phase II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS4627–TPS4627. 3 indexed citations

Simon, Nicholas I., Scot A. Niglio, Giovanni Maria Iannantuono, et al.. (2023). A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies.. Journal of Clinical Oncology. 41(16_suppl). 4571–4571. 1 indexed citations

Niglio, Scot A., Daniel M. Girardi, Lisa M. Cordes, et al.. (2021). A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies.. Journal of Clinical Oncology. 39(15_suppl). TPS4599–TPS4599. 3 indexed citations

Girardi, Daniel M., Scot A. Niglio, Amir Mortazavi, et al.. (2020). Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.. Journal of Clinical Oncology. 38(15_suppl). 5037–5037. 2 indexed citations

Niglio, Scot A., Daniel M. Girardi, Amir Mortazavi, et al.. (2020). Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).. Journal of Clinical Oncology. 38(15_suppl). 5039–5039. 3 indexed citations

10.

Tian, Xue‐Fei, Narayan Shivapurkar, Zheng Wu, et al.. (2016). Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer. Oncology Letters. 11(3). 1645–1650. 22 indexed citations

11.

Wu, Zheng, Andrew Gabrielson, Jimmy J. Hwang, et al.. (2015). Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology. 76(6). 1309–1314. 39 indexed citations

12.

Díaz‐Cruz, Edgar S., Aline Charabaty, Simeng Suy, et al.. (2014). Human Pancreatic Cancer-Associated Stellate Cells Remain Activated after in vivo Chemoradiation. Frontiers in Oncology. 4. 102–102. 27 indexed citations

13.

Collins, Sean P., Rebecca Slack, Gary Tse, et al.. (2013). Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Radiation Oncology. 8(1). 44–44. 83 indexed citations

14.

Pishvaian, Michael J., Hongkun Wang, Aiwu Ruth He, et al.. (2013). A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology. 31(4_suppl). 147–147. 18 indexed citations

15.

Go, K.G., et al.. (1994). The Effect of Steroid Treatment on Lipocortin Immunoreactivity of Rat Brain. Mediators of Inflammation. 3(3). 177–180. 7 indexed citations

16.

Go, K.G., Jeff W. M. Bulte, Lisa Ley, et al.. (1993). Our approach towards developing a specific tumour-targeted MRI contrast agent for the brain. European Journal of Radiology. 16(3). 171–175. 17 indexed citations

17.

Postmus, Pieter E., Lisa Ley, Anneke Y. van der Veen, et al.. (1988). Two small cell lung cancer cell lines established from rigid bronchoscope biopsies. European Journal of Cancer and Clinical Oncology. 24(4). 753–763. 11 indexed citations

18.

Harms, Geert, Harry van Goor, J Koudstaal, Lisa Ley, & Mj Hardonk. (1988). Double immunohistochemical demonstration of antigen expression and DNA-incorporated 5-bromodeoxyuridine in frozen and plastic embedded sections.. PubMed. 36. 353–9. 13 indexed citations

19.

Harms, G., Harry van Goor, J Koudstaal, Lisa Ley, & Mj Hardonk. (1986). Immunohistochemical demonstration of DNA-incorporated 5-bromodeoxyuridine in frozen and plastic embedded sections. Histochemistry and Cell Biology. 85(2). 139–143. 85 indexed citations

20.

Smets, Lou A., Lisa Ley, & J.G. Collard. (1975). Contact-mediated changes in cytoagglutination. Experimental Cell Research. 95(1). 95–102. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact